Skip to main content
. 2022 Sep 27;187(6):823–845. doi: 10.1530/EJE-22-0263

Table 2.

Medical history of patients included in the current study. Data are presented as median (Q1, Q3) or as n (%).

Characteristics Values
Patients, n 223
Disease duration in years 5.00 (2.00; 10.0)
IGF1 value at diagnosis 731 (491; 923)
GH random value at diagnosis 11.1 (5.60; 25.7)
GH nadir post OGTT at diagnosis 8.8 (4.03; 17.3)
Adenoma size at diagnosis
 Microadenoma 80 (35.8%)
 Macroadenoma 143 (64.2%)
Neurosurgery
 Transsphenoidal 167 (74.9%)
 Transcranial 9 (4.04%)
 None 47 (21.1%)
Hormonal deficit
 1 39 (17.6%)
 2 16 (7.2%)
 3 5 (2.2%)
Replacement therapy*
 No 177 (79.4%)
 Yes 46 (20.6%)

*For hormonal deficiency at diagnosis.

GH, growth hormone; IGF1, insulin-like growth factor 1; OGTT, oral glucose tolerance test.